Duska gains $5.57M in financing, names CEO

Bala Cynwyd, PA-based Duska Therapeutics has raised $5.75 million in financing from three institutional investors. The company also announced that James S. Kuo, M.D., M.B.A., is the company's new CEO. He also serves as Duska's board chairman, and previously was CEO of BioMicro Systems. Duska is focused on developing new medicines to treat cardiovascular disease by modulating the P2 receptor in the heart and lungs.

"We are excited to complete this first financing by institutional investors. We intend to use the proceeds to develop several of our drugs to an inflection point in valuation," said Kuo.

- see the release on the financing
- and this announcement on Kuo's appointment

Relatd Article:
The top five VC deals of 2007. Report

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.